Researchers presented an observational study at the European Respiratory Society Congress in Barcelona, Spain, revealing that diabetes and weight loss drug semaglutide is associated with a nearly 40 per cent reduction in asthma attacks. The findings highlight potential respiratory benefits for patients with airway diseases.
Real-World Data Links Semaglutide to Fewer Asthma and COPD Flare-Ups
A newly highlighted real-world medical analysis suggests that patients managing type 2 diabetes or obesity with specific metabolic therapies may also experience notable improvements in their respiratory health. Researchers examined electronic medical records from tens of thousands of patients in the UK who started taking glucagon-like peptide-1 receptor agonists, commonly known as GLP-1 receptor agonists, or a different diabetes medication called sulfonylureas.
The investigation, led by academic teams and presented at the European Respiratory Society Congress in Barcelona, Spain, focused on whether these treatments correlated with a drop in acute respiratory attacks for individuals diagnosed with asthma or chronic obstructive pulmonary disease. While GLP-1 treatments are widely prescribed to manage blood sugar and slow digestion, their impact on airway diseases had not been captured as primary endpoints in past clinical trials.
The data pointed to distinct advantages depending on the specific medication and condition involved. Prof Chloe Bloom, clinical associate professor in respiratory epidemiology at the National Heart and Lung Institute at Imperial College London, outlined the core figures during the presentation.
“The effect was strongest with semaglutide especially in people with asthma, where use of semaglutide appears to be associated with nearly 40 per cent reduction in asthma attacks. Semaglutide also led to a 20 per cent reduction in COPD flare-ups.”
Prof Chloe Bloom, clinical associate professor in respiratory epidemiology at the National Heart and Lung Institute at Imperial College London, via Yahoo News UK
Weighing the Real-World Evidence Against Methodological Limits
Because the project relied on routine health records rather than a randomized controlled trial, it establishes a correlation rather than a definitive causal link.
Dr Marie Spreckley, researcher on the prevention of diabetes and related metabolic disorders at the University of Cambridge, pointed out that individuals prescribed semaglutide may differ in clinical care, treatment adherence, or underlying health habits from those taking other medications. These unmeasured variables could influence the observed outcomes.
Furthermore, Prof Stephen Burgess, professor of biostatistics at the University of Cambridge, emphasized that because the findings stem from an upcoming conference summary rather than a finalized peer-reviewed paper, certain analytical details remain under review.
Dr Alexander Mathioudakis, chairman of the European Respiratory Society’s Group on Airway Pharmacology and Treatment, noted that obesity and metabolic dysfunction remain frequently under-recognized factors in airway diseases.
Patient Guidance and Next Steps for Metabolic Research
Patients are strongly advised against seeking semaglutide solely to manage respiratory symptoms outside of established prescribing guidelines for diabetes or weight management.
Dr Samantha Walker, director of research and innovation at Asthma + Lung UK, underscored the broader implications for future scientific investigations, noting that the data reinforce the need to evaluate respiratory outcomes in upcoming trials of metabolic therapies.
“This promising study indicates that people already taking semaglutide for diabetes or obesity experience a significant reduction in asthma attacks and COPD flare ups. The positive effects of semaglutide were significant for patients with asthma and COPD compared with other GLP-1 agnostics but stronger in asthma.”
Dr Samantha Walker, director of research and innovation at Asthma + Lung UK, via Yahoo News UK
Future clinical trials incorporating lung function metrics, symptom scores, and exacerbation rates will be required to confirm whether semaglutide delivers a direct biological benefit to patients with airways disease.
